(Source: Ergomed plc) Ergomed's Co-Development Partner Ferrer Initiates Phase IIa Study of Lorediplon in Patients with Insomnia Guildford, UK - 14 July 2015: Ergomed plc, (LSE: ERGO or 'Ergomed') a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, is pleased to report that the first patient has been recruited into the Phase IIa study it is undertaking with Ferrer under the parties' co-development agreement. The study is a Phase IIa clinical trial testing the efficacy, safety and tolerability profile of Lorediplon in adult patients with insomnia disorder. Miroslav Reljanovic, Chief Executive Officer...
↧